The Organized American Medical Profession's Response to Financial Conflicts of Interest: 1890-1992

1992 ◽  
Vol 70 (4) ◽  
pp. 703 ◽  
Author(s):  
Marc A. Rodwin
Keyword(s):  
American Medical ◽  
Conflicts Of Interest ◽  
Financial Conflicts Of Interest

scholarly journals A161 PREVALENCE OF FINANCIAL CONFLICTS OF INTEREST (FCOI) AMONG PROPENSITY-SCORE MATCHED RETROSPECTIVE STUDIES EVALUATING BIOLOGIC THERAPEUTICS FOR IBD

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 168-170
Author(s):  
K Elsolh ◽  
D Tham ◽  
M A Scaffidi ◽  
R Bansal ◽  
J Li ◽  
...  
Keyword(s):  
Propensity Score ◽  
Propensity Score Matching ◽  
Retrospective Studies ◽  
Conflicts Of Interest ◽  
Cochrane Library ◽  
High Burden ◽  
Real World Evidence ◽  
Full Text Retrieval ◽  
Financial Conflicts Of Interest ◽  
Matched Comparison

Abstract Background Inflammatory Bowel Disease (IBD) studies have commonly relied on real-world evidence to evaluate different therapies. An emerging idea has been the use of propensity score matching as a statistical method to account for baseline characteristics in IBD patients. In retrospective studies, propensity score matching of patients helps reduce treatment assignment bias and mimic the effects of randomization. Recently, propensity-score matching has become an important tool in IBD studies comparing biologic therapeutics. Biologic medications are among the highest-grossing drugs worldwide, and their pharmaceutical producers make considerable payments to physicians to market them. In spite of this, there is a lack of evidence examining the role of undue industry influence among propensity-score matched comparative studies evaluating biologic therapeutics for IBD. Aims Given the documented association between IBD biologics and FCOI, we hypothesize a high burden of FCOI in propensity-score matched studies. The aim of this study was to evaluate the prevalence of disclosed & undisclosed financial conflicts of Interest (FCOI) in propensity-score matched comparison studies evaluating biologics for IBD. Methods We developed & ran a librarian-reviewed systematic search on EMBASE, MEDLINE, and Cochrane Library databases for all propensity-score matched retrospective studies comparing biologics for the treatment of IBD. Full-text retrieval & screening was performed on all studies in duplicate. 16 articles were identified. Industry payments to authors were only considered FCOI if they were made by a company producing a biologic that was included in the comparison study. Disclosed FCOI were identified by authors’ interests disclosures in full-texts. Any undisclosed FCOI among US authors were identified using the Centre for Medicare and Medicaid Services (CMS) Open Payments Database, which collects industry payments to physicians. Results Based on a preliminary analysis of 16 studies, there was at least one author with a relevant FCOI in 14 (88%) of the 16 studies. 14 studies (88%) had at least one disclosed FCOI, while 6 studies (37.5%) had at least one undisclosed FCOI. Among studies with disclosed FCOI, a mean of 40.2% (SD = 23.4%) of authors/study reported FCOI. Among studies with undisclosed FCOI, a mean of 18.8% (SD = 7.0%) of authors/study reported FCOI. The total dollar value of FCOIs was $1,974,328.3. The median conflict dollar value was $5,576.6 (IQR: $321.6 to $36,394.9). Conclusions We found a high burden of undisclosed FCOI (37.5%) among authors of propensity-score matched studies evaluating IBD biologics. Given the potential for undue industry influence stemming from such payments, authors should ensure better transparency with industry relationships. Funding Agencies None

Surrogacy of Financial Conflicts of Interest

2013 ◽  
Vol 31 (21) ◽  
pp. 2645-2647
Author(s):  
Ralph M. Meyer
Keyword(s):  
Conflicts Of Interest ◽  
Financial Conflicts Of Interest

scholarly journals Transparency ethics in practice: Revisiting financial conflicts of interest disclosure forms in clinical practice guidelines

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0182856 ◽  
Author(s):  
Yidan Lu ◽  
Derek J. Jones ◽  
Nour Sharara ◽  
Tonya Kaltenbach ◽  
Loren Laine ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Conflicts Of Interest ◽  
Financial Conflicts Of Interest

scholarly journals Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health

PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0203179
Author(s):  
Michelle M. Mello ◽  
Lindsey Murtagh ◽  
Steven Joffe ◽  
Patrick L. Taylor ◽  
Yelena Greenberg ◽  
...  
Keyword(s):  
Public Health ◽  
Conflicts Of Interest ◽  
Financial Conflicts Of Interest ◽  
Institutional Oversight ◽  
Schools Of Medicine

scholarly journals P.013 Conflicts of interest in neurosurgical research - comparing voluntary physician disclosure to mandatory company data

2016 ◽  
Vol 43 (S2) ◽  
pp. S24-S24 ◽  
Author(s):  
PJ McDonald ◽  
ER Shon ◽  
AV Kulkarni
Keyword(s):  
Voluntary Disclosure ◽  
Conflicts Of Interest ◽  
Average Rate ◽  
Industry Data ◽  
Ethical Implications ◽  
The Us ◽  
Financial Conflicts Of Interest ◽  
Author Disclosure ◽  
Open Payments

Background: Industry involvement in neurosurgical research is common, creating financial conflicts of interest (COIs). Most journals require voluntary disclosure of financial COIs. In 2013, the Sunshine Act (SA) was passed in the US, mandating industry disclosure of all payments to physicians. The accuracy of voluntary disclosure can now be determined by comparing voluntary author disclosure with industry data. Methods: We reviewed disclosure statements and calculated rates of voluntary disclosure in major neurosurgical journals before (2011) and after (2013) the Sunshine Act to determine if voluntary disclosure increased after its implementation. We then determined the accuracy of voluntary disclosure in 2013, comparing voluntary disclosure with industry disclosure on the Open Payments Database (OPD). Mean, median and range of industry payments to neurosurgeons were calculated Results: Voluntary disclosure significantly increased in JNS-Spine only (10.7% to 35.4%,p<0.001) after implementation of the SA. The average rate of non-disclosure in all journals studied was 38.3% (Range 33.8%-42.2%)$32,598,522.97 of industry payments were provided to 656 authors in the five-month period studied (Average $49,692.87/author) Conclusions: Voluntary COI disclosure in JNS- Spine increased after implementation of the Sunshine Act. Industry payments to physicians publishing in neurosurgery journals are common and rates of non-disclosure of COIs are high. The ethical implications of COIs and non-disclosure are discussed.

Sign in / Sign up

Export Citation Format

Share Document